Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Cardiovascular Disease Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Cardiovascular Disease Drugsmarket, defines the market attractiveness level of Cardiovascular Disease Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Cardiovascular Disease Drugs industry, describes the types of Cardiovascular Disease Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Cardiovascular Disease Drugs market and the development prospects and opportunities of Cardiovascular Disease Drugs industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Cardiovascular Disease Drugs market in Chapter 13.
By Player:
Bayer
Johnson＆Johnson
Actelion Pharmaceuticals
Novartis
United Therapeutics Corporation
Boehringer Ingelheim
Daiichi Sankyo Company Limited
Astellas Pharma
Merck
Takeda Pharmaceutical
Pfizer
Sanofi
AstraZeneca
Hoffmann-La Roche
By Type:
Heparin
Coumadin
Sectral
Zebeta
Lopressor
Toprol XL
Norvasc
Lotrel
Others
By End-User:
Asischemic Heart Disease
Dyslipidemia
Stroke
Thrombosis
Atherosclerosis
Coronary Artery Diseases
Peripheral Artery Disease
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Cardiovascular Disease Drugs Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Cardiovascular Disease Drugs Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Cardiovascular Disease Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Cardiovascular Disease Drugs Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Cardiovascular Disease Drugs Market Analysis and Outlook to 2022
-
7.1 Global Cardiovascular Disease Drugs Consumption (2017-2022)
-
7.2 United States Cardiovascular Disease Drugs Consumption (2017-2022)
-
7.3 Europe Cardiovascular Disease Drugs Consumption (2017-2022)
-
7.4 China Cardiovascular Disease Drugs Consumption (2017-2022)
-
7.5 Japan Cardiovascular Disease Drugs Consumption (2017-2022)
-
7.6 India Cardiovascular Disease Drugs Consumption (2017-2022)
-
7.7 South Korea Cardiovascular Disease Drugs Consumption (2017-2022)
8 Region and Country-wise Cardiovascular Disease Drugs Market Analysis and Outlook to 2028
-
8.1 Global Cardiovascular Disease Drugs Consumption Forecast (2022-2028)
-
8.2 United States Cardiovascular Disease Drugs Consumption Forecast (2022-2028)
-
8.3 Europe Cardiovascular Disease Drugs Consumption Forecast (2022-2028)
-
8.4 China Cardiovascular Disease Drugs Consumption Forecast (2022-2028)
-
8.5 Japan Cardiovascular Disease Drugs Consumption Forecast (2022-2028)
-
8.6 India Cardiovascular Disease Drugs Consumption Forecast (2022-2028)
-
8.7 South Korea Cardiovascular Disease Drugs Consumption Forecast (2022-2028)
9 Global Cardiovascular Disease Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Cardiovascular Disease Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Heparin Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Coumadin Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Sectral Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Zebeta Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Lopressor Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Toprol XL Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Norvasc Consumption and Growth Rate (2017-2022)
-
9.1.8 Global Lotrel Consumption and Growth Rate (2017-2022)
-
9.1.9 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Cardiovascular Disease Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Asischemic Heart Disease Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Dyslipidemia Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Stroke Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Thrombosis Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Atherosclerosis Consumption and Growth Rate (2017-2022)
-
9.2.6 Global Coronary Artery Diseases Consumption and Growth Rate (2017-2022)
-
9.2.7 Global Peripheral Artery Disease Consumption and Growth Rate (2017-2022)
-
9.2.8 Global Others Consumption and Growth Rate (2017-2022)
10 Global Cardiovascular Disease Drugs Market Outlook by Types and Applications to 2028
-
10.1 Global Cardiovascular Disease Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Heparin Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Coumadin Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Sectral Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Zebeta Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Lopressor Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global Toprol XL Consumption Forecast and Growth Rate (2022-2028)
-
10.1.7 Global Norvasc Consumption Forecast and Growth Rate (2022-2028)
-
10.1.8 Global Lotrel Consumption Forecast and Growth Rate (2022-2028)
-
10.1.9 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Cardiovascular Disease Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Asischemic Heart Disease Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Dyslipidemia Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Stroke Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Thrombosis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Atherosclerosis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.6 Global Coronary Artery Diseases Consumption Forecast and Growth Rate (2022-2028)
-
10.2.7 Global Peripheral Artery Disease Consumption Forecast and Growth Rate (2022-2028)
-
10.2.8 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Cardiovascular Disease Drugs Import and Export Analysis (Top 5 Countries)
-
11.1 Global Cardiovascular Disease Drugs Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Cardiovascular Disease Drugs Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Cardiovascular Disease Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Cardiovascular Disease Drugs Market Competitive Analysis
-
14.1 Bayer
-
14.1.1 Bayer Company Details
-
14.1.2 Bayer Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Bayer Cardiovascular Disease Drugs Product and Service
-
14.2 Johnson＆Johnson
-
14.2.1 Johnson＆Johnson Company Details
-
14.2.2 Johnson＆Johnson Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Johnson＆Johnson Cardiovascular Disease Drugs Product and Service
-
14.3 Actelion Pharmaceuticals
-
14.3.1 Actelion Pharmaceuticals Company Details
-
14.3.2 Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Actelion Pharmaceuticals Cardiovascular Disease Drugs Product and Service
-
14.4 Novartis
-
14.4.1 Novartis Company Details
-
14.4.2 Novartis Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Novartis Cardiovascular Disease Drugs Product and Service
-
14.5 United Therapeutics Corporation
-
14.5.1 United Therapeutics Corporation Company Details
-
14.5.2 United Therapeutics Corporation Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 United Therapeutics Corporation Cardiovascular Disease Drugs Product and Service
-
14.6 Boehringer Ingelheim
-
14.6.1 Boehringer Ingelheim Company Details
-
14.6.2 Boehringer Ingelheim Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Boehringer Ingelheim Cardiovascular Disease Drugs Product and Service
-
14.7 Daiichi Sankyo Company Limited
-
14.7.1 Daiichi Sankyo Company Limited Company Details
-
14.7.2 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product and Service
-
14.8 Astellas Pharma
-
14.8.1 Astellas Pharma Company Details
-
14.8.2 Astellas Pharma Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Astellas Pharma Cardiovascular Disease Drugs Product and Service
-
14.9 Merck
-
14.9.1 Merck Company Details
-
14.9.2 Merck Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Merck Cardiovascular Disease Drugs Product and Service
-
14.10 Takeda Pharmaceutical
-
14.10.1 Takeda Pharmaceutical Company Details
-
14.10.2 Takeda Pharmaceutical Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Takeda Pharmaceutical Cardiovascular Disease Drugs Product and Service
-
14.11 Pfizer
-
14.11.1 Pfizer Company Details
-
14.11.2 Pfizer Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Pfizer Cardiovascular Disease Drugs Product and Service
-
14.12 Sanofi
-
14.12.1 Sanofi Company Details
-
14.12.2 Sanofi Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 Sanofi Cardiovascular Disease Drugs Product and Service
-
14.13 AstraZeneca
-
14.13.1 AstraZeneca Company Details
-
14.13.2 AstraZeneca Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.13.3 AstraZeneca Cardiovascular Disease Drugs Product and Service
-
14.14 Hoffmann-La Roche
-
14.14.1 Hoffmann-La Roche Company Details
-
14.14.2 Hoffmann-La Roche Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.14.3 Hoffmann-La Roche Cardiovascular Disease Drugs Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Cardiovascular Disease Drugs
-
Figure Cardiovascular Disease Drugs Picture
-
Table Global Cardiovascular Disease Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Cardiovascular Disease Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Cardiovascular Disease Drugs Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Cardiovascular Disease Drugs Consumption by Country (2017-2022)
-
Figure United States Cardiovascular Disease Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Cardiovascular Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure China Cardiovascular Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Cardiovascular Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Cardiovascular Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Cardiovascular Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Cardiovascular Disease Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Cardiovascular Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Cardiovascular Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Cardiovascular Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Cardiovascular Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Cardiovascular Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Cardiovascular Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Heparin Consumption and Growth Rate (2017-2022)
-
Figure Global Coumadin Consumption and Growth Rate (2017-2022)
-
Figure Global Sectral Consumption and Growth Rate (2017-2022)
-
Figure Global Zebeta Consumption and Growth Rate (2017-2022)
-
Figure Global Lopressor Consumption and Growth Rate (2017-2022)
-
Figure Global Toprol XL Consumption and Growth Rate (2017-2022)
-
Figure Global Norvasc Consumption and Growth Rate (2017-2022)
-
Figure Global Lotrel Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Asischemic Heart Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Dyslipidemia Consumption and Growth Rate (2017-2022)
-
Figure Global Stroke Consumption and Growth Rate (2017-2022)
-
Figure Global Thrombosis Consumption and Growth Rate (2017-2022)
-
Figure Global Atherosclerosis Consumption and Growth Rate (2017-2022)
-
Figure Global Coronary Artery Diseases Consumption and Growth Rate (2017-2022)
-
Figure Global Peripheral Artery Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Heparin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Coumadin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Sectral Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Zebeta Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lopressor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Toprol XL Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Norvasc Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lotrel Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Asischemic Heart Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dyslipidemia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Stroke Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Thrombosis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Atherosclerosis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Coronary Artery Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Peripheral Artery Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Cardiovascular Disease Drugs Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Cardiovascular Disease Drugs Export by Region (Top 5 Countries) (2017-2028)
-
Table Bayer (Foundation Year, Company Profile and etc.)
-
Table Bayer Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Cardiovascular Disease Drugs Product and Service
-
Table Johnson＆Johnson (Foundation Year, Company Profile and etc.)
-
Table Johnson＆Johnson Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson＆Johnson Cardiovascular Disease Drugs Product and Service
-
Table Actelion Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Actelion Pharmaceuticals Cardiovascular Disease Drugs Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Cardiovascular Disease Drugs Product and Service
-
Table United Therapeutics Corporation (Foundation Year, Company Profile and etc.)
-
Table United Therapeutics Corporation Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table United Therapeutics Corporation Cardiovascular Disease Drugs Product and Service
-
Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)
-
Table Boehringer Ingelheim Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Cardiovascular Disease Drugs Product and Service
-
Table Daiichi Sankyo Company Limited (Foundation Year, Company Profile and etc.)
-
Table Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product and Service
-
Table Astellas Pharma (Foundation Year, Company Profile and etc.)
-
Table Astellas Pharma Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharma Cardiovascular Disease Drugs Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Cardiovascular Disease Drugs Product and Service
-
Table Takeda Pharmaceutical (Foundation Year, Company Profile and etc.)
-
Table Takeda Pharmaceutical Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Pharmaceutical Cardiovascular Disease Drugs Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Cardiovascular Disease Drugs Product and Service
-
Table Sanofi (Foundation Year, Company Profile and etc.)
-
Table Sanofi Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Cardiovascular Disease Drugs Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Cardiovascular Disease Drugs Product and Service
-
Table Hoffmann-La Roche (Foundation Year, Company Profile and etc.)
-
Table Hoffmann-La Roche Cardiovascular Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hoffmann-La Roche Cardiovascular Disease Drugs Product and Service
-
